184 related articles for article (PubMed ID: 22252660)
41. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
[TBL] [Abstract][Full Text] [Related]
42. Cancer-drug discovery and cardiovascular surveillance.
Groarke JD; Cheng S; Moslehi J
N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
[No Abstract] [Full Text] [Related]
43. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
44. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study.
Millot F; Suttorp M; Versluys AB; Kalwak K; Nelken B; Ducassou S; Bertrand Y; Baruchel A
Eur J Cancer; 2020 Sep; 136():107-112. PubMed ID: 32668374
[TBL] [Abstract][Full Text] [Related]
45. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.
Okabe S; Tauchi T; Tanaka Y; Katagiri S; Kitahara T; Ohyashiki K
Blood; 2013 Oct; 122(17):3086-8. PubMed ID: 24159169
[No Abstract] [Full Text] [Related]
46. Ponatinib: a third-generation inhibitor for the treatment of CML.
Wehrle J; Pahl HL; von Bubnoff N
Recent Results Cancer Res; 2014; 201():99-107. PubMed ID: 24756787
[TBL] [Abstract][Full Text] [Related]
47. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
48. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
[TBL] [Abstract][Full Text] [Related]
49. [Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib].
Motomura Y; Arai K; Yoshifuji K; Sonokawa S; Suzuki S; Kumagai T
Rinsho Ketsueki; 2019; 60(1):33-38. PubMed ID: 30726822
[TBL] [Abstract][Full Text] [Related]
50. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Chakraborty R; Mukkamalla SK; Singam K; Calderon N
Korean J Intern Med; 2014 Nov; 29(6):827-9. PubMed ID: 25378984
[No Abstract] [Full Text] [Related]
51. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
[No Abstract] [Full Text] [Related]
52. Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.
Mayer K; Gielen GH; Willinek W; Müller MC; Wolf D
Leukemia; 2014 Apr; 28(4):976-7. PubMed ID: 24170029
[No Abstract] [Full Text] [Related]
53. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL?
Thomas X
Lancet Oncol; 2015 Nov; 16(15):1451-1453. PubMed ID: 26432047
[No Abstract] [Full Text] [Related]
54. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
[TBL] [Abstract][Full Text] [Related]
55. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
Sasaki H; Mitani S; Kusumoto S; Marumo Y; Asano A; Yoshida T; Narita T; Ito A; Yano H; Ri M; Ishida T; Komatsu H; Iida S
Int J Hematol; 2019 Jul; 110(1):119-123. PubMed ID: 30879266
[TBL] [Abstract][Full Text] [Related]
56. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
Mian AA; Schüll M; Zhao Z; Oancea C; Hundertmark A; Beissert T; Ottmann OG; Ruthardt M
Leukemia; 2009 Sep; 23(9):1614-21. PubMed ID: 19369965
[TBL] [Abstract][Full Text] [Related]
57. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Haddad FG; Sasaki K; Bidikian A; Issa GC; Kadia T; Jain N; Alvarado Y; Short NJ; Pemmaraju N; Loghavi S; Patel KP; Kanagal-Shamanna R; Yilmaz M; Masarova L; Jabbour E; Kantarjian H
Am J Hematol; 2023 Oct; 98(10):1619-1626. PubMed ID: 37485584
[TBL] [Abstract][Full Text] [Related]
58. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
59. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.
Jain P; Kantarjian H; Jabbour E; Gonzalez GN; Borthakur G; Pemmaraju N; Daver N; Gachimova E; Ferrajoli A; Kornblau S; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Sep; 2(9):e376-83. PubMed ID: 26436130
[TBL] [Abstract][Full Text] [Related]
60. Does ponatinib cross the blood-brain barrier?
Abid MB; De Mel S
Br J Haematol; 2017 Nov; 179(3):497-498. PubMed ID: 27352067
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
